Lipoplex-based targeted gene therapy for the suppression of tumours with VEGFR expression by producing anti-angiogenic molecules

Lipoplex-based targeted gene therapy for the suppression of tumours with VEGFR expression by producing anti-angiogenic molecules

Abstract Background The anti-angiogenic fusion protein RBDV-IgG1 Fc (RBDV), which comprises the receptor-binding domain of vascular endothelial growth factor-A (VEGF-A), has shown antitumour effects by reducing angiogenesis in vivo. This study used the cationic lipoplex lipo-PEG-PEI-complex (LPPC) t...

Full description

Bibliographic Details
Main Authors: Shu-Yi Ho, Pin-Rong Chen, Chia-Hung Chen, Nu-Man Tsai, Yu-Hsin Lin, Chen-Si Lin, Cheng-Hsun Chuang, Xiao-Fan Huang, Yi-Lin Chan, Yen-Ku Liu, Chen-Han Chung, Shun-Long Weng, Kuang-Wen Liao
Format: Article
Language:English
Published: BMC 2020-04-01
Series:Journal of Nanobiotechnology
Subjects:
LPPC
Gene therapy
Anti-angiogenesis
RBDV
VEGFR
Online Access:http://link.springer.com/article/10.1186/s12951-020-00610-9

Internet

http://link.springer.com/article/10.1186/s12951-020-00610-9

Similar Items